SCHEMBL1338765

SCHEMBL1338765

COC(=O)[C@@H]1COC(c2ccc(OC)cc2)=N1

nearest known ligand 0.76

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
ALDH1A1 P00352 1/20 0.53
MAPT P10636 1/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1338762 1.00 MEN1 (0.56) MEN1KMT2AALDH1A1MAPTNPC1
SCHEMBL21825774 0.87
SCHEMBL21825776 0.87
SCHEMBL25012007 0.86
SCHEMBL2221193 0.86
SCHEMBL3367044 0.85 MEN1 (0.44) MEN1KMT2A
SCHEMBL771298 0.85
SCHEMBL6708480 0.85
SCHEMBL12245522 0.85
SCHEMBL21825814 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3862083-B1 CATALYST FOR ASYMMETRIC HYDROGENATION OF COMPOUND CONTAINING CARBON DOUBLE BOND GLACEUM INC (KR) 2023-03-08 EP disclosed
US-11420988-B2 Catalyst for asymmetric hydrogenation of compound containing carbon double bond GLACEUM, INC. (KR) 2022-08-23 US disclosed
US-20210395282-A1 CATALYST FOR ASYMMETRIC HYDROGENATION OF COMPOUND CONTAINING CARBON DOUBLE BOND GLACEUM, INC. (KR) 2021-12-23 US disclosed
EP-3862083-A1 CATALYST FOR ASYMMETRIC HYDROGENATION OF COMPOUND CONTAINING CARBON DOUBLE BOND Glaceum, Inc. (KR) 2021-08-11 EP disclosed
US-8063205-B2 Method for producing 2-oxazoline analogue or 1,3-oxazine analogue NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2011-11-22 US disclosed
US-20090281309-A1 METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2009-11-12 US disclosed
EP-1956012-A1 METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE National University Corporation Hokkaido University (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281309-A1 METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE OXA1L, SULT1A1, DAO MEN1 4342/4885KMT2A 2952/4885ALDH1A1 41/4885
US-20210395282-A1 CATALYST FOR ASYMMETRIC HYDROGENATION OF COMPOUND CONTAINING CARBON DOUBLE BOND INF2, DCX, HDHD5 MEN1 2874/4885KMT2A 753/4885ALDH1A1 464/4885
US-11420988-B2 Catalyst for asymmetric hydrogenation of compound containing carbon double bond INF2, DCX, HDHD5 MEN1 2874/4885KMT2A 753/4885ALDH1A1 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.